CoChat

Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent

Open access
Artis, Dean R., Lin, Jack J., Zhang, Chao, Wang, Weiru, Mehra, Upasana, Perreault, Mylene, Erbe, David, Krupka, Heike I., England, Bruce P., Arnold, James, Plotnikov, Alexander N., Marimuthu, Adhirai, Nguyen, Hoa, Will, Sarah, Signaevsky, Maxime, Kral, John, Cantwell, John, Settachatgull, Calvin, Yan, Douglas S., Fong, Daniel, Oh, Angela, Shi, Shenghua, Womack, Patrick, Powell, Benjamin, Habets, Gaston, West, Brian L., Zhang, Kam Y. J., Milburn, Michael V., Vlasuk, George P., Hirth, K. Peter, Nolop, Keith, Bollag, Gideon, Ibrahim, Prabha N., Tobin, James F. · 2009 · Proceedings of the National Academy of Sciences
Cited by 148

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Abstract

In a search for more effective anti-diabetic treatment, we used a process coupling low-affinity biochemical screening with high-throughput co-crystallography in the design of a series of compounds that selectively modulate the activities of all three peroxisome proliferator-activated receptors (PPARs), PPARα, PPARγ, and PPARδ. Transcriptional transactivation assays were used to select compounds from this chemical series with a bias toward partial agonism toward PPARγ, to circumvent the clinically observed side effects of full PPARγ agonists. Co-crystallographic characterization of the lead molecule, indeglitazar, in complex with each of the 3 PPARs revealed the structural basis for its PPAR pan-activity and its partial agonistic response toward PPARγ. Compared with full PPARγ-agonists, indeglitazar is less potent in promoting adipocyte differentiation and only partially effective in stimulating adiponectin gene expression. Evaluation of the compound in vivo confirmed the reduced adiponectin response in animal models of obesity and diabetes while revealing strong beneficial effects on glucose, triglycerides, cholesterol, body weight, and other metabolic parameters. Indeglitazar has now progressed to Phase II clinical evaluations for Type 2 diabetes mellitus (T2DM).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1073/pnas.0811325106

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 148

Metadata

Authors
Artis, D. R., Lin, J. J., Zhang, C., Wang, W., Mehra, U., Perreault, M., Erbe, D., Krupka, H. I., England, B. P., Arnold, J., Plotnikov, A. N., Marimuthu, A., Nguyen, H., Will, S., Signaevsky, M., Kral, J., Cantwell, J., Settachatgull, C., Yan, D. S., Fong, D., Oh, A., Shi, S., Womack, P., Powell, B., Habets, G., West, B. L., Zhang, K. Y. J., Milburn, M. V., Vlasuk, G. P., Hirth, K. P., Nolop, K., Bollag, G., Ibrahim, P. N., & Tobin, J. F.
Venue
Proceedings of the National Academy of Sciences
Published
2009-01-06
Volume
106
Issue
1
Pages
262-267
ISSN
  • 0027-8424 (ISSN-L)
  • 1091-6490
OpenAlex
W2090460655
Cited by
148
References
5
FWCI
3.97
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. https://app.cochat.ai/papers/10.1073/pnas.0811325106
The paper
Artis, D. R., Lin, J. J., Zhang, C., Wang, W., Mehra, U., Perreault, M., Erbe, D., Krupka, H. I., England, B. P., Arnold, J., Plotnikov, A. N., Marimuthu, A., Nguyen, H., Will, S., Signaevsky, M., Kral, J., Cantwell, J., Settachatgull, C., Yan, D. S., . . . Tobin, J. F. (2009). Scaffold-based discovery of indeglitazar, a PPAR pan-active anti-diabetic agent. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.0811325106

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.